Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

Cholestatic Liver Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zydus Site US001, Indianapolis, Indiana, United States
Contact: Study coordinator (Mandy Cruz) · mandcruz@iu.edu

Study leads

Deven Parmar
Study Director
Zydus Therapeutics Inc.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Hepatic Impairment · Cirrhosis · Cholestatic Liver Disease

Abroad (travel likely)RecruitingPHASE1

Indianapolis, United States

DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE

Cholestatic Liver Disease · Progressive Familial Intrahepatic Cholestasis

Abroad (travel likely)Recruiting

Milan, Italy

Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis

Cholestatic Liver Disease · Intrahepatic Cholestasis · Progressive Familial Intrahepatic Cholestasis

Abroad (travel likely)Recruiting

Bologna, Italy · Modena, Italy

Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers

Hepatobiliary Cancers · Progressive Familial Intrahepatic Cholestasis (PFIC) · Cholestatic Liver Disease

Abroad (travel likely)Recruiting

Bologna, Italy · Bologna, Italy